Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

Key Inclusion Criteria: * Participants legally competent to sign and give informed consent and, if appropriate, assent as required by local laws. * Males and females ages 9 years and older at the time of consent. * Clinical diagnosis of seborrheic dermatitis of at least 3 months duration at Screening as determined by the Investigator. Stable disease for the past 4 weeks. * Seborrheic dermatitis up to 20% BSA involvement. Involvement may be of the scalp and/or face and/or trunk and/or intertriginous areas. * An Investigator Global Assessment (IGA) disease severity of at least Moderate ('3') at Baseline. * Overall Assessment of Erythema and Overall Assessment of Scaling scores of at least Moderate ('2') at Baseline. * Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2). * Females of non-childbearing potential must either be post-menopausal with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization. * Subjects in good health as judged by the Investigator. * Subjects are considered reliable and capable of adhering to the Protocol and visit schedule according to the Investigator judgment. Key Exclusion Criteria: * Subjects who cannot discontinue treatment with therapies for the treatment of seborrheic dermatitis prior to the Baseline visit and during the study. * Planned excessive exposure of treated area(s) to either natural or artif…